FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
17. September 2024 12:55 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for...
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
16. September 2024 04:15 ET
|
Novartis Pharma AG
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1Results remain...
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
28. August 2024 01:15 ET
|
Novartis Pharma AG
Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction1 Results add to growing body of...
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
07. August 2024 19:30 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a...
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
18. Juli 2024 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im zweiten Quartal um +11% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +19% (kWk, +17% USD) Das Umsatzwachstum...
Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
18. Juli 2024 01:00 ET
|
Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RCRésultats du deuxième trimestre (T2)Chiffre d’affaires net en hausse de +11% (tcc1, +9% USD) et du résultat opérationnel core, de +19% (tcc, +17% USD) La...
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
18. Juli 2024 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto...
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
31. Mai 2024 08:00 ET
|
Novartis Pharma AG
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs....
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
30. Mai 2024 18:01 ET
|
Novartis Pharma AG
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
25. Mai 2024 06:15 ET
|
Novartis Pharma AG
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction...